Stavudine 200mg + Lamivudine 150mg + Nevirapine 30mg

This antiretroviral formulation combines two nucleoside reverse transcriptase inhibitors with a non-nucleoside reverse transcriptase inhibitor, designed for use in specific clinical settings for the management of HIV-1 infection, in line with applicable treatment protocols.

Product Details

Therapeutic Class
Nucleoside Reverse Transcriptase Inhibitors (Stavudine + Lamivudine)
Non-Nucleoside Reverse Transcriptase Inhibitor (Nevirapine)

Indication
Treatment of HIV-1 infection in adults and pediatric patients as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations and national treatment policies.

Dosage & Administration
To be administered as per recommended dosing schedules based on patient age, body weight, and clinical condition, or as prescribed by a healthcare professional.

To be used strictly as part of a combination ART regimen.

Storage
Store below 30°C in a dry place, protected from light and moisture.

Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.

Pack Size

30 Tablets